Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 10, Pages 5242-5248Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b01912
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC) of Australia [APP1045140, APP1120853]
- National Health and Medical Research Council of Australia (NHMRC) [APP1020411, APP1117602, APP1059960]
- NHMRC [APP1145769]
- Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS) program via Therapeutic Innovation Australia (TIA)
Ask authors/readers for more resources
Herein we describe the development of a focused series of functionalized pyridazin-3(2H)-one-based formyl peptide receptor (FPR) agonists that demonstrate high potency and biased agonism. The compounds described demonstrated biased activation of prosurvival signaling, ERK1/2 phosphorylation, through diminution of the detrimental FPR1/2-mediated intracellular calcium (Ca-i(2+)) mobilization. Compound 50 showed an EC50 of 0.083 mu M for phosphorylation of ERK1/2 and an approximate 20-fold bias away from Ca-i(2+) mobilization at the hFPR1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available